receptor agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-MSH |
| Molecular mass | Approximately 1025 Da | Peptide-scale molecule |
| Route | Subcutaneous injection | Intranasal form used in early research |
| Common synonyms | PT-141; bremelanotide acetate | Research code and salt form |
| Typical storage | 2-8 °C, protected from light | Unopened vial condition |
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
A plastic bottle with a disposable liner was eventually tested at George Washington University Hospital and marketed by Playtex. Innovations such as the introduction of a working check valve in the nipple (to provide unidirectional flow of the liquid food) appeared as early as 1948 in a patent to J.W. Less. This technology was picked up by others including Owens-Illinois Glass, eventually making its way into Gerber and all modern pressure-balancing bottle designs. It is also used for adult drinking cups and various other products requiring fluid flow under vacuum. The modern business of producing bottles in the developed world is substantial. For 2018, the global baby bottle market was valued at US$2.6 billion. In 1999 it was reported that the UK "feeding and sterilising equipment sector ... stands at £49m… [where] [s]ales of feeding bottles account for 39%" or £19.1m of that market.
At the time, only Mike Piazza (35), David Justice (28), and Darryl Strawberry (26) had hit more home runs as an NL rookie since 1972, and only Piazza had more RBI (112). Helton finished second to Kerry Wood of the Chicago Cubs in the voting for NL Rookie of the Year. The Tennessee Sports Hall of Fame named Helton its 1998 Professional Athlete of the Year. In 1999, Helton put up a slash line of .320/.395/.587. He slugged 35 home runs and drove in 113 RBI, while also drawing 68 walks. On June 19, in a 10–2 home win over the Florida Marlins, Helton hit for the cycle. He fell one hit shy of hitting for a second cycle on four occasions during the 1999 season. Had he managed to repeat the performance that season, he would have become only the second player since 1900 to pull it off, the other being Babe Herman in 1931.
== Investments == Mubadala has invested in logistics software startup Turvo, Alphabet-owned self-driving technology company Waymo, Reliance Jio Platforms, UK life sciences company Envision, and Telegram. Mubadala is a parent company of GlobalFoundries, a semiconductor foundry company. Mubadala owns stakes in numerous companies, including a 7.5 percent share in the Carlyle Group. In 2007 Mubadala announced an initial investment in AMD. As of 2017 Mubadala had a stake of 12.9 percent in the chipmaker. In 2019 Mubadala sold its entire stake in AMD. In 2019, Mubadala and Falcon Edge Capital established Abu Dhabi Catalyst Partners, a $1 billion joint venture to invest in financial institutions. In November 2020, Mubadala transferred ownership of two information technology companies it previously owned, Injazat and Khazna, to artificial intelligence company, G42, and took a stake in G42. In 2021, Mubadala purchased a 2.6% stake in En+ Group, a manufacturer of green aluminum, from Polina Yumasheva, the former wife of Russian businessman Oleg Deripaska. The same year, Mubadala purchased MetrôRio, the company that holds the operations for the Rio de Janeiro metro, from Invepar. In 2016, Mubadala became the biggest external shareholder at Investcorp, after acquiring 20% stakes in the Bahraini firm. In 2023, a former UK minister, Gerry Grimstone was criticized for conducting and not declaring 13 meetings with Mubadala and Khaldoon al-Mubarak, after acquiring the role as an adviser and the chair of planned climate fund at Investcorp.
Sources: en.wikipedia.org
Maryanoff (born 1949), American organic/medicinal chemist Maud Menten (1879–1960), Canadian biochemist Helen Vaughn Michel (born 1932), American nuclear chemist Alexandra Navrotsky (born 1943), American geochemist Dorothy Virginia Nightingale (1902–2000), American organic chemist Yolanda Ortiz (chemist) (1924–2019), Argentine chemist, environmentalist Kathlyn Parker, American organic chemist Emma Parmee, British-born medicinal/organic chemist Marguerite Perey (1909–1975), French physicist, student of Marie Curie, discovered the element francium in 1939 Mary Engle Pennington (1872–1952), American food chemist Eva Philbin (1914–2005), Irish chemist Iphigenia Photaki (1921–1983), Greek organic chemist Darshan Ranganathan (1941–2001), Indian organic chemist Mildred Rebstock (1919–2011), American Pharmaceutical chemist Sibyl Martha Rock (1909–1981), American pioneer in mass spectrometry and computing Elizabeth Rona (1890–1981), Hungarian (naturalized American) nuclear chemist and polonium expert Mary Swartz Rose (1874–1941), Nutrition chemist Melanie Sanford (born 1975), American organic chemist Maxine L. Savitz, American Chemist Patsy Sherman (1930–2008), American chemist, co-inventor of Scotchgard Odette L.
== Beyond plant disease == Potyvirus RNA codes for at least seven different proteins. One of them is a protease. The TEV protease is a highly site-specific protease that biochemists have used to their advantage to create a protein purification system by incorporating TEV protease's recognition site into protein purification tags. A gene construct is created containing the protein of interest fused to a TEV protease recognition site, followed by an affinity tag, such as a polyhistidine-tag. Following affinity chromatography, the purified protein is then treated with TEV protease. TEV protease cleaves at its recognition site, removing the affinity tag. This allows for affinity purification of proteins that are not well-behaved when fused to protein tags.
DBS research targets include, but are not limited to, the following areas: Cg25 for depression, the anterior limb of the internal capsule for depression as well as obsessive-compulsive disorder (OCD), centromedian/parafasicularis, centromedian thalamic nuclei and the subthalamic nucleus for OCD, anorexia and Tourette syndrome; the nucleus accumbens and ventral striatum have also been assayed for depression and pain.
=== Pharmacodynamics === Phenylpiracetam is a racetam and is described as a stimulant. Racetams have a variety of different pharmacological activities and have varying effects. For example, phenylpiracetam is a stimulant, piracetam is a nootropic, and levetiracetam is an anticonvulsant. The mechanisms of action of most racetams, with some exceptions, are unknown. Phenylpiracetam is a racemic mixture. (R)-Phenylpiracetam is the most active enantiomer and is much more potent in stimulating locomotor activity than (S)-phenylpiracetam, which is ineffective. However, (S)-phenylpiracetam retains some activity in most pharmacological tests. On the other hand, in one animal test, the passive avoidance test, (S)-phenylpiracetam appeared to be antagonistic of (R)-phenylpiracetam.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.
Earlier approaches were largely hormonal or psychological in focus, whereas this compound acts on central melanocortin signalling. It is not a vasodilator and does not share the mechanism of phosphodiesterase inhibitors. Head-to-head comparative data are limited.
Placebo responses in desire trials are large, so the average drug-placebo separation is small. Reporting therefore relies on validated questionnaires with statistical ranges. Individual responses vary widely.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.